FDA recommends discontinuation of OTC Zantac

The FDA has requested that manufacturers withdraw all prescription and over-the-counter ranitidine drugs and advised patients to discontinue taking over-the-counter versions of the drug, according to an agency release.This move is the most recent step in the agency’s ongoing investigation of N-Nitrosodimethylamine (NDMA) contamination in ranitidine medications, according to an agency safety alert. The FDA said it determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures may result in consumer exposure to unacceptableRead More

Share on facebook
Share on twitter
Share on linkedin